Key result
Targeted next-generation sequencing identified hot spots and doubly heterozygous mutations in TNNI3, LMNA, and MYH7 genes associated with severe phenotypes in familial cardiomyopathy.
Why the study?
Does targeted next-generation sequencing identify pathogenic mutations in Chinese patients with familial cardiomyopathy?
Observational
Does targeted next-generation sequencing identify pathogenic mutations in Chinese patients with familial cardiomyopathy?
Targeted next-generation sequencing is an effective tool for identifying pathogenic mutations, including doubly heterozygous mutations that correlate with severe phenotypes, in patients with familial cardiomyopathy.
Case report data should not change practice; leaves open the utility of targeted NGS for mutation detection and risk stratification in familial cardiomyopathy.
As a common cardiac disease mainly caused by gene mutations in sarcomeric cytoskeletal, calcium-handling, nuclear envelope, desmosomal, and transcription factor genes, inherited cardiomyopathy is becoming one of the major etiological factors of sudden cardiac death (SCD) and heart failure (HF). This disease is characterized by remarkable genetic heterogeneity, which makes it difficult to screen for pathogenic mutations using Sanger sequencing. In the present study, three probands, one with familial hypertrophic cardiomyopathy (FHCM) and two with familial dilated cardiomyopathy (FDCM), were recruited together with their respective family members. Using next-generation sequencing technology (NGS), 24 genes frequently known to be related to inherited cardiomyopathy were screened. Two hot spots (TNNI3-p.Arg145Gly, and LMNA-p.Arg190Trp) and double (LMNA-p.Arg190Trp plus MYH7-p.Arg1045His) heterozygous mutations were found to be highly correlated with familial cardiomyopathy. FDCM patients with doubly heterozygous mutations show a notably severe phenotype as we could confirm in our study; this indicates that the double mutations had a dose effect. In addition, it is proposed that genetic testing using NGS technology can be used as a cost-effective screening tool and help guide the treatment of patients with familial cardiomyopathy particularly regarding the risk of family members who are clinically asymptomatic.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2015) conducted an observational in Familial Cardiomyopathy. Targeted Next-Generation Sequencing (NGS) was evaluated on Identification of pathogenic mutations in 24 cardiomyopathy-related genes. Targeted next-generation sequencing identified hot spots and doubly heterozygous mutations in TNNI3, LMNA, and MYH7 genes associated with severe phenotypes in familial cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: